Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib Combined With DAG Regimen for Refractory/Relapsed AML
NCT05982756Phase 1Unknown
- Sponsor
- Zhongnan Hospital of Wuhan University
- Start
- Jan 2020
- Primary completion
- Sep 2023
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bortezomib in acute myeloid leukemia (AML) (2 arms), sponsored by Zhongnan Hospital of Wuhan University. Primary endpoint: Rate of bone marrow blasts. Status: unknown.
02
Drugs
bortezomib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05982756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05982756.